Axsome Therapeutics Inc
NASDAQ:AXSM
Axsome Therapeutics Inc
NASDAQ:AXSM
Price:
157.87
USD
-2.05%
Market Closed
Market Cap:
$8.1B
Relative Value
The Relative Value of one
AXSM
stock under the Base Case scenario is
117.64
USD.
Compared to the current market price of 157.87 USD,
Axsome Therapeutics Inc
is
Overvalued by 25%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AXSM
Relative Value
Base Case
117.64
USD
Overvaluation 25%
Multiples Across Competitors
AXSM Competitors Multiples
Axsome Therapeutics Inc Competitors
Axsome Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
8B USD | 12.4 | -43.3 | -49.4 | -46.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867.4B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.4B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.8B CHF | 4.2 | 20 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
220.3B GBP | 5 | 28.9 | 16 | 22.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.9B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.5B USD | 2.5 | 17 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
